Stelara Settlement Gives Amgen US Ustekinumab Entry Date
Agreement With Johnson & Johnson’s Janssen Offers Amgen 1 January 2025 Launch Date
A settlement reached in US patent litigation over Janssen’s Stelara will allow Amgen to launch its ABP 654 ustekinumab biosimilar no later than 1 January 2025. It remains to be seen whether other ustekinumab developers will follow suit.
